Skip to content
PubMed This is a summary of 98 peer-reviewed journal articles Updated
Nephrology · Hypertensive Nephrosclerosis

Hypertensive Nephrosclerosis: A Patient Guide

At a Glance

Hypertensive nephrosclerosis is long-term kidney damage linked to high blood pressure that may cause no symptoms. Regular kidney filtration and urine protein tests, individualized blood pressure treatment, kidney-protective medicines, and lower sodium intake help monitor and protect kidney health.

How to Use This Guide: This resource is educational. Your own eGFR, UACR, and medical history determine what applies to you. Do not start, stop, or change your treatment based on this guide alone. Always follow your clinician’s specific plan.

Presumed hypertensive nephrosclerosis is a clinical pattern of chronic kidney damage associated with long-term high blood pressure. For many years, it was viewed as a simple mechanical problem: high pressure physically damaging delicate vessels and filters. However, we now understand it involves a complex interplay between your circulatory system and your immune response [1]. In some individuals, particularly those of recent African ancestry, specific genetics like the APOL1 gene variants can also increase the susceptibility of the kidneys to injury [2].

Because the kidneys are highly resilient, this damage often progresses silently for years without causing physical symptoms. This “silent” nature makes routine laboratory monitoring the cornerstone of your care. By tracking your eGFR (kidney filtration rate) and your UACR (protein leakage in the urine), your care team can detect changes in kidney health long before you feel sick [3]. Keep in mind that Chronic Kidney Disease (CKD) is generally established by an abnormality lasting at least three months.

While a diagnosis of presumed hypertensive kidney disease is often made based on your medical history and these lab trends, it is essentially a clinical assumption. In cases where the lab results show atypical or unusual patterns, a kidney biopsy may be discussed to ensure the damage isn’t actually being caused by a different disease that requires a different treatment [4].

The goal of modern management is comprehensive organ protection. This is achieved through strict, individualized blood pressure management and protective medications like ACE inhibitors, ARBs, and SGLT2 inhibitors, which are designed to reduce the stress on the kidney’s filters [5]. These medical treatments work best when supported by lifestyle modifications, particularly a reduction in dietary sodium [6]. By coordinating these tools with your medical team, you can work to stabilize your kidney function and protect your long-term health [7].

Glossary of Key Terms

  • eGFR (estimated Glomerular Filtration Rate): A blood test that estimates how much blood your kidneys filter per minute. It determines your CKD “G” stage (G1 to G5).
  • UACR (Urine Albumin-to-Creatinine Ratio): A test measuring the amount of albumin (protein) leaking into your urine. It determines your “A” stage (A1, A2, A3).
  • Albuminuria/Proteinuria: The presence of excess protein in the urine, indicating filter damage.
  • Glomeruli: The microscopic filters inside your kidneys.
  • Podocytes: Specialized cells that wrap around the glomeruli to prevent protein from leaking out.
  • Arteriolosclerosis: The thickening and hardening of small arteries.
  • Fibrosis: Deep tissue scarring.
  • KFRE (Kidney Failure Risk Equation): A validated formula using age, sex, eGFR, and UACR to estimate the probability of kidney failure over 2 or 5 years.
  • ACE Inhibitor / ARB: Blood pressure medications that also lower pressure inside the kidney filters to reduce protein leakage.
  • SGLT2 Inhibitor: A class of medications originally for diabetes that helps protect kidney function and reduce failure risk.

Common questions in this guide

What is hypertensive nephrosclerosis?
Hypertensive nephrosclerosis is a pattern of chronic kidney damage associated with long-term high blood pressure. It can develop silently, so kidney function and urine protein testing are important even when you feel well.
How do eGFR and UACR show whether my kidneys are healthy?
eGFR estimates how well your kidneys filter blood, while UACR measures albumin, a type of protein, leaking into your urine. Clinicians use both results and their trends to assess kidney health, and chronic kidney disease generally requires an abnormality lasting at least three months.
Is a kidney biopsy needed to diagnose hypertensive nephrosclerosis?
Not always. The diagnosis is often presumed from your medical history and patterns in kidney function and urine tests, but a biopsy may be discussed when results are unusual or suggest another disease that needs different treatment.
Can APOL1 gene variants increase the risk of kidney damage?
Certain APOL1 gene variants can increase the kidneys’ susceptibility to injury in some people, particularly those of recent African ancestry. A genetic factor may be considered alongside blood pressure history and laboratory results when your clinician evaluates the cause of kidney disease.
What treatments can help protect my kidneys?
Individualized blood pressure control is central to treatment. ACE inhibitors, ARBs, and SGLT2 inhibitors may reduce stress on the kidney filters, while lifestyle changes such as reducing dietary sodium can support blood pressure management.
Which matters more for treatment: my eGFR or my UACR?
Both tests provide different information and are usually interpreted together. eGFR reflects kidney filtration, while UACR reflects protein leakage, so your care team uses both results and their changes over time to judge kidney health and treatment response.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my medical history, do you believe high blood pressure is the primary cause of my kidney damage, or could it be a symptom of an underlying genetic factor?
  2. 2.Which of my lab results—the eGFR or the urine protein (UACR)—is currently the most important indicator of how well my treatment is working?
  3. 3.Are there specific lifestyle changes, like a target for daily sodium intake, that would make my blood pressure medications more effective?
  4. 4.If we are unable to reach our blood pressure goals with my current medications, what is the next step in my treatment plan?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (7)
  1. 1

    The Role of Non-Coding RNA in the Pathogenesis of Hypertensive Nephropathy.

    Plewa P, Figiel K, Ćmil M, et al.

    Cells 2026; (15(8)) doi:10.3390/cells15080701.

    PMID: 42041569
  2. 2

    Hypertensive nephrosclerosis: wider kidney biopsy indications may be needed to improve diagnostics.

    Hallan SI, Øvrehus MA, Bjørneklett R, et al.

    Journal of internal medicine 2021; (289(1)):69-83 doi:10.1111/joim.13146.

    PMID: 32613703
  3. 3

    Clinicopathological predictors for progression of chronic kidney disease in nephrosclerosis: a biopsy-based cohort study.

    Yamanouchi M, Hoshino J, Ubara Y, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2019; (34(7)):1182-1188 doi:10.1093/ndt/gfy121.

    PMID: 29788462
  4. 4

    Clinical Phenotypes and Long-term Prognosis in White Patients With Biopsy-Verified Hypertensive Nephrosclerosis.

    Øvrehus MA, Oldereid TS, Dadfar A, et al.

    Kidney international reports 2020; (5(3)):339-347 doi:10.1016/j.ekir.2019.12.010.

    PMID: 32154455
  5. 5

    Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.

    ,

    Lancet (London, England) 2022; (400(10365)):1788-1801 doi:10.1016/S0140-6736(22)02074-8.

    PMID: 36351458
  6. 6

    Altered dietary salt intake for people with chronic kidney disease.

    McMahon EJ, Campbell KL, Bauer JD, et al.

    The Cochrane database of systematic reviews 2021; (6()):CD010070 doi:10.1002/14651858.CD010070.pub3.

    PMID: 34164803
  7. 7

    Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.

    Cheung AK, Chang TI, Cushman WC, et al.

    Kidney international 2021; (99(3)):559-569 doi:10.1016/j.kint.2020.10.026.

    PMID: 33637203

This guide is for informational purposes only and does not constitute medical advice. Your clinician should interpret your eGFR, UACR, and blood pressure readings and guide any treatment changes.

Get notified when new evidence is published on nephrosclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.